SAFE Drugs Act would tighten FDA oversight of compounded GLP-1 medicines

A bill in Congress would limit how many compounded copies of approved medicines a traditional pharmacy can make each month and require annual FDA reporting on shipments that cross state lines, part of a wider push to tighten oversight of compounded GLP-1 drugs.

The Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025, H.R. 6509, arrived in the House on December 9, 2025, and was referred to the Committee on Energy and Commerce ^[1]. Senator Jim Banks, an Indiana Republican, introduced the Senate companion, with Senator Martin Heinrich, a New Mexico Democrat, as cosponsor, according to a press release dated February 6, 2026 ^[2].

What the bill would change

For 503A compounding pharmacies, the measure would write the definition of "essentially a copy of a commercially available drug product" into federal law and block those pharmacies from producing more than 20 units a month of such a drug unless the preparation is tailored to an individual patient ^[1]. The FDA has published guidance on what counts as "essentially a copy," but that guidance does not create legally enforceable duties for compounders, according to an analysis by the law firm Dykema ^[1].

Cross-state sellers would pick up a new reporting duty. Pharmacies, outsourcing facilities, or physicians that ship more than 20 compounded prescriptions containing an active ingredient found in an approved medicine to patients in another state would file annual reports with the FDA describing the products and quantities involved ^[1]. Compounding done on a hospital's own premises for that hospital's patients is carved out of the requirement ^[1].

Outsourcing facilities, which operate under section 503B, would need an FDA inspection before they begin compounding a new drug, plus follow-up inspections every two years if they make more than 100 products in a calendar year ^[1]. The Senate version would also raise the base user fee for those facilities to an amount set by HHS ^[2].

Why it matters for patients

Compounded drugs do not go through FDA review for safety, effectiveness, or quality before they reach patients ^[1]. They are intended for people whose needs an approved product cannot meet. Demand for compounded versions of semaglutide and tirzepatide built up online and through telehealth platforms, and kept going even after those drugs came off the FDA shortage list ^[1].

In practice, the 20-unit ceiling and the reporting threshold fall on operations making large volumes for patients in other states, rather than a pharmacy preparing one tailored prescription nearby. Shabbir Safdar of the Partnership for Safe Medicines said the bill seeks to restrict illegal mass compounding "while preserving the essential role of compounding in serving patients whose medical needs can't be met with a commercial product" ^[2].

The American Diabetes Association said it recommends against compounded GLP-1 and dual GIP/GLP-1 medications because of uncertainty about their content, safety, quality, and effectiveness, and it supports added FDA oversight of those practices ^[2].

Regulators are not waiting on the legislation. In September 2025, the FDA and HHS began an enforcement initiative aimed at misleading advertising in the compounded drug space, issuing warning letters to telehealth providers and companies promoting compounded GLP-1s and flagging "generic" or "clinically proven" claims as potentially misbranded ^[1]. A coalition of 38 state attorneys general has pressed the FDA to escalate investigations, inspections, and warning letters, pointing to unknown contaminants, incorrect dosages, and online sales of active GLP-1 ingredients labeled "research use only" ^[1].

What happens next

The House bill remains in committee, with no vote recorded ^[1]. The Senate companion was introduced in early February 2026 ^[2]. No hearing dates, committee votes, or floor schedule for either bill have been reported ^[1][2], and whether Congress will pass the measure, or what a final version would contain, is not yet known.